Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2018
At a glance
- Drugs Rebastinib (Primary) ; Eribulin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- 22 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
- 22 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 02 Jun 2017 Trial design presented at 53rd Annual Meeting of the American Society of Clinical Oncology.